IgA Nephropathy
NephCure has announced the first IgA Nephropathy (IgAN) Awareness Day, happening September 26, 2024.
The FDA has granted full approval to sparsentan to slow kidney function decline in adults with primary IgA nephropathy.
Information on a possible association between chronic tonsillitis and IgA nephropathy (IgAN) has been lacking.
Prevalence of IgA nephropathy (IgAN) and a summary of treatment patterns across Asian countries are lacking.
Urinary inflammatory biomarkers may be considered as alternative predictive biomarkers in patients with IgAN.
Researchers studied the LM pattern of glomerular injury and mesangial C3 staining in IgA nephropathy (IgAN).
The FDA has granted accelerated approval of Fabhalta (iptacopan) to reduce proteinuria in adults with IgA nephropathy.
The American Kidney Fund has launched the Rare Kidney Disease Action Network.
Atrasentan showed a statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN).
IgA nephropathy (IgAN) is on the cusp of a transformational change in its treatment.
Advertisement
Advertisement
